EGFR and adenocarcinoma: Adenocarcinoma tumors were mostly pan-wild type (36.5%), KRAS mutated (35.4%), and EGFR mutated (16.3%) while squamous cell carcinoma tumors were even more predominantly pan-wild type (85.5%) (Supplementary Figure 1).